DHA-paclitaxel
A chemotherapeutic agent used in cancer treatment
| DHA-paclitaxel | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
DHA-paclitaxel is a chemotherapeutic agent that is used in the treatment of various types of cancer. It is a conjugate of docosahexaenoic acid (DHA) and paclitaxel, designed to improve the delivery and efficacy of paclitaxel in cancer therapy.
Mechanism of Action[edit | edit source]
DHA-paclitaxel works by exploiting the natural affinity of DHA for cancer cells. Docosahexaenoic acid is an omega-3 fatty acid that is preferentially taken up by tumor cells. Once inside the cell, the DHA is cleaved, releasing paclitaxel, which then exerts its cytotoxic effects by stabilizing microtubules and inhibiting cell division.
Pharmacokinetics[edit | edit source]
The conjugation of DHA to paclitaxel alters the pharmacokinetic profile of the drug. This modification allows for a more targeted delivery to tumor cells, potentially reducing the systemic toxicity associated with paclitaxel. The DHA moiety facilitates the transport of the drug across cell membranes, enhancing its accumulation in cancerous tissues.
Clinical Applications[edit | edit source]
DHA-paclitaxel has been investigated for its use in treating various cancers, including breast cancer, lung cancer, and ovarian cancer. Clinical trials have shown that it may offer advantages over traditional paclitaxel formulations, such as improved tolerability and enhanced antitumor activity.
Side Effects[edit | edit source]
The side effect profile of DHA-paclitaxel is similar to that of paclitaxel, with common adverse effects including neutropenia, peripheral neuropathy, and alopecia. However, the DHA conjugation may reduce the severity of some side effects due to its targeted delivery mechanism.
Research and Development[edit | edit source]
Research into DHA-paclitaxel continues, with ongoing studies aimed at optimizing its formulation and delivery. Investigations are also focused on understanding the full range of its antitumor activity and potential applications in combination therapies.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
